Meta-Analysis
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Feb 15, 2025; 17(2): 98927
Published online Feb 15, 2025. doi: 10.4251/wjgo.v17.i2.98927
Efficacy of sorafenib combined with transarterial chemoembolization in the treatment of advanced hepatocellular carcinoma: A meta-analysis
Mei Xu, Si-Rui Zhou, Ya-Ling Li, Chen-Hao Zhang, Da-Zhong Liao, Xiao-Li Wang
Mei Xu, Si-Rui Zhou, Da-Zhong Liao, Xiao-Li Wang, Department of Oncology, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, Sichuan Province, China
Ya-Ling Li, Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China
Chen-Hao Zhang, Department of Breast and Thyroid Surgery, The First People's Hospital of Yibin, Yibin 644000, Sichuan Province, China
Co-corresponding authors: Da-Zhong Liao and Xiao-Li Wang.
Author contributions: Xu M initiated the study and was instrumental in its conception. Both Xu M and Zhou SR played significant roles in conducting the literature review, data extraction, quality assessment, data analysis, and manuscript drafting; Xu M and Li YL made substantial contributions to enhancing the manuscript through improvements in language and style, as well as protocol development; Xu M and Zhang CH actively participated in data analysis and facilitated critical discussions that enriched the research. Liao DZ and Wang XL meticulously reviewed the final manuscript, providing their endorsement for publication. Both authors, Liao DZ and Wang XL are from the same hospital institution and have jointly guided and supervised the entire research project. They have also been responsible for arranging the division of labor and coordinating the collaboration between all team members. Additionally, they have actively monitored the progress and processes of the research. Their collaborative efforts in the design and execution of the study, as well as their significant contributions to the manuscript, have been essential. Given their equal involvement and leadership throughout the research process, we have designated them as co-corresponding authors. This designation reflects their shared responsibility for both the project and the manuscript and ensures that the communication responsibilities are appropriately represented by both individuals.
Supported by Sichuan Science and Technology Program, No. 2022YFS0625.
Conflict-of-interest statement: The authors declare that they have no competing interests.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Li Wang, MD, Doctor, Department of Oncology, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, No. 182 Chunhui Road, Luzhou 646000, Sichuan Province, China. wxl0427easy@163.com
Received: July 9, 2024
Revised: November 22, 2024
Accepted: December 10, 2024
Published online: February 15, 2025
Processing time: 192 Days and 22.1 Hours
Core Tip

Core Tip: This meta-analysis synthesizes current research to assess the efficacy of combining sorafenib with transarterial chemoembolization (TACE), aiming to enhance survival outcomes in patients with advanced hepatocellular carcinoma (HCC). Our comprehensive review, adhering to PRISMA guidelines, included twelve studies and 1174 patients, revealing that the combination therapy significantly improves both overall survival and progression-free survival compared to sorafenib or TACE alone. These results advocate for the integration of this combined approach in clinical practice, potentially setting a new benchmark in the treatment protocols for advanced HCC.